Neurocrine Biosciences (NBIX) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $142.12 -0.82%
EPS Growth %: -12.0%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -12.0%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.24, $0.12 better than the analyst estimate of $1.12. Revenue for the quarter came in at $412 million versus the consensus estimate of $408.87 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Venture Global rises after QatarEnergy supply talks reported
- SS&C Technologies shares fall on weak Q4 revenue outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
